08 additional projects not completed in time

July 24, Kang Yuan Pharmaceutical industry 2010.5 Annual performance report, 1-June, the company realized operating income of 625.1086 million yuan, an increase of 43.53%, belong to the listed company shareholder net profit of 91.3611 million yuan, the year-on-year increase of 30.08%.　　It is worth mentioning that the 08-year project, which was originally expected to be completed in June 2009, has so far had two projects not completed, less than 40% completion rates and three projects that have not reached the predetermined revenue. Net profit year-on-year increase of 30% gross margin of the pharmaceutical industry is mainly engaged in Chinese medicine preparation, health care products manufacturing and sales business. In the first half of 2010, the company took effective measures to reduce the price of raw and auxiliary materials to the company's cost pressure, appropriate increase in marketing investment. During the reporting period, the company's leading varieties of Guizhi fuling capsules, hot poison ning injection, Days Shu capsule, waist bi Tong capsules sales revenue than the same period last year, rapid growth.　　Semi-annual reports show that the company consolidated statements to achieve business income of 625.1086 million yuan, an increase of 43.53%, operating profit of 96.2634 million yuan, an increase of 28.19%, belong to the listed company shareholders of the net profit of 91.3611 million yuan, an increase of 30.08%. Although through the cost of control to increase marketing efforts, the company's first half of the net profit increased 30%, but the reporting period because of 37, honeysuckle and other parts of the original price of medicinal materials rose,　　resulting in the company consolidated statement gross profit margin with a year-on-year decline of 2.74%, the parent company's gross profit margin decreased by 2.12%, of which the hot poison ning injection as the leading varieties of injection dosage form of the gross profit drop 12.76%. So far, among the four pharmaceutical listed companies that have been reported in the semi-annual report, only the Kang-yuan pharmaceutical industry has proposed a profit distribution scheme, and the company intends to increase its share capital to all shareholders by increasing the proportion of 3 shares per 10 shares to 95,918,467 shares. After the increase, the total share capital of the company increased from 319,728,224 shares to 415,646,691 shares.　　According to the new equity dilution, the company's basic earnings per share for the 2010.5 year is 0.22 yuan/share. Additional projects not completed in time yet to contribute to income at the same time, the company disclosed in the 2010.5 Annual report on the progress of public offerings in 2008: Three projects in the modern Chinese Medicine injection production Technology project has been completed, and the other two projects to kill the pain capsule industrialization Project, The starting rate of the innovative Chinese Medicine Research and Safety Evaluation Center project is less than 40%.　　The company admitted in the semi-annual report that the project did not meet the expected revenue. 2008 the company through the issuance of the way to raise funds 282 million yuan. According to the prospectus, the company promised three project construction period of 2 years, according to the plan should be at the end of June 2009, three projects have entered the normal production phase. However, according to the disclosure of 2010.5 Annual report, the industrial project of Jie-Jie analgesic capsule was proposed to invest 62.68 million yuan, actual input of 19.593 million yuan, project Progress 31.26%, another project to innovate Traditional Chinese medicine researchThe progress of completion of the project with the Safety Assessment Centre was 39.82% per year, and the completion time was still less than 40%. 280 million of the fund-raising has not yet produced two years of benefits, and for the specific reasons for the delay in the completion of the project, the company in the 2010.5 Annual report has not made any explanation, only mentioned "fund-raising project is still in the construction period, the fund-raising has not yet been used." ”